| | Webinar: 2021 Apollo Healthcare Predictions Thursday, February 4, 2021 | 1pm ET / 10am PT With so much disruption from COVID-19, this year’s global insights will provide a unique window into the minds of those professionals perhaps most tested by 2020 and their hopes and perspectives for 2021. Register Now! |
Sorry, Europe: AstraZeneca follows Pfizer/BioNTech in cutting back EU vaccine delivery plans Illumina CEO says U.S. lags behind on catching COVID-19 mutations: CNBC Biden orders OSHA to explore new work safety standards for workers at risk of COVID-19 Vaccine experts are excited about mRNA's success in COVID, but it's not time to 'walk away' from traditional shots: panel Pfizer's R&D president Dolsten: Not taking government cash made us more nimble for COVID-19 vaccine AstraZeneca vaccine production unscathed after fire breaks out at Serum Institute of India Complex Eli Lilly's COVID-19 antibody shows it can prevent the disease. But will doctors use it? ONC investing $20M to boost COVID-19 vaccine data sharing efforts Healthcare roundup: HCA partners to create new venture to bolster domestic PPE manufacturing Biopharma roundup: Bharat's vaccine safe in phase 1; Europe to question Pfizer over shot delivery delays BIO lays off staff to adapt to another year of virtual events Beyond COVID-19, where will biopharma focus in 2021? Featured Story | By Eric Sagonowsky As AstraZeneca nears European authorization for its highly anticipated COVID-19 vaccine, the drugmaker has notified officials that initial shipments will come in lighter than originally expected. read more |
| |
|---|
|
Top Stories By Conor Hale The CDC predicts that fast-spreading variants could become the predominant coronavirus mutation by the end of March. read more By Robert King President Biden issued an executive order calling for OSHA to explore new emergency protections for healthcare workers fighting COVID-19. read more By Eric Sagonowsky The COVID-19 pandemic has raised the profile of mRNA vaccines in a dramatic way in about a year. Looking forward, the technology holds more promise and could displace traditional shots in some diseases, experts said, but it's not time to give up on well-known vaccine platforms, either. read more By Ben Adams Mikael Dolsten, M.D., Ph.D., Pfizer’s chief scientific officer and president for worldwide R&D and medical, is clear: The company's COVID-19 vaccine is here because of a decade of R&D work and taking major risks itself while not asking for government handouts. read more By Fraiser Kansteiner Five people have died after a fire broke out at Serum Institute of India's home base in the western state of Pune, the company revealed Thursday, but the blaze, now under control, won't hamper production of COVID-19 vaccines, company CEO Adar Poonawalla said. read more By Angus Liu Eli Lilly’s bamlanivimab was the first antibody drug the FDA authorized to treat COVID-19. Now, the Indianapolis pharma has data showing the therapy prevents symptomatic infections. The catch? The data are limited to long-term care facilities, where vaccination is now underway—and despite their utility, antibodies are having a tough time catching on. read more By Heather Landi As the nation continues to ramp up distribution of COVID-19 vaccines, providers will need to track vaccination progress and identify patients who are due to receive the second dose. To boost data sharing, ONC is investing nearly $20 million in CARES Act funds to help increase data sharing between health information exchanges and immunization information systems. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Conor Hale Bharat's vaccine Covaxin was safe and triggered an immune response in a phase 1 study. The European Commission wants to get to the bottom of additional Pfizer delivery delays. Poland is considering legal action against the company if promised doses aren't delivered, while France could impose sanctions on Pfizer for future delays. read more By Nick Paul Taylor The Biotechnology Innovation Organization has made “some staff reductions” as it faces up to the prospect of another year without the face-to-face events that were central to its pre-pandemic operation. read more By Amirah Al Idrus Fighting the pandemic will remain a top priority in 2021, but just because we’re in a pandemic doesn’t mean all other diseases have stopped plaguing humanity. We asked executives which areas might see a resurgence this year, and neurology emerged as a popular horse to bet on. read more |
